Does CBD lower blood sugar? Only one randomized study has tested cannabidiol on its own in people with diabetes: published in 2016 in Diabetes Care, it measured no effect on blood glucose after 13 weeks of use. When it comes to CBD, type 1 and type 2 diabetes do not raise the same questions, and for a person on insulin or oral medication, the first risk lies in interactions.
What this article covers
- Diabetes in a few key points, before talking about CBD
- How does CBD act on glucose metabolism?
- What animal studies show
- The 2016 trial on type 2 diabetes, the only one testing CBD alone
- Cannabis use and insulin: what observational studies say
- What are the risks of CBD for people with diabetes?
- Type 1 and type 2 diabetes: different expectations
- CBD and diabetes: the precautions to know
- CBD and blood sugar: answers to frequently asked questions
Diabetes in a few key points, before talking about CBD
Diabetes is a chronic disease defined by an excess of sugar in the blood, known as hyperglycemia. According to the 10th edition of the International Diabetes Federation's Atlas (2021), about 537 million adults aged 20 to 79 live with this disease worldwide. Two forms dominate, and they have almost nothing in common in their origin.
- Type 1 diabetes
- The immune system destroys the beta cells of the pancreas, which produce insulin. The person must receive insulin every day, for life. This form often appears in children or young adults.
- Type 2 diabetes
- The body still produces insulin, but the tissues respond poorly to it (insulin resistance) and production gradually wears out. Weight, diet and a sedentary lifestyle weigh heavily in its onset; it is the most common form in adults.
Updated October 22, 2026: abstracts reviewed on PubMed (Diabetes Care 2016, American Journal of Medicine 2013, Autoimmunity 2006), European package leaflet for Epidyolex reviewed on the EMA website.
Insulin is the hormone that lets glucose enter the cells. When it is lacking or works poorly, the sugar level rises and, over the long term, complications set in: damage to the nerves (neuropathy), the eyes (retinopathy), the kidneys, the heart and the blood vessels. Any serious discussion of CBD and diabetes must distinguish between these two forms, because a substance that calms an immune reaction does not play the same role as a substance that improves insulin sensitivity. Studies also often cite the endocannabinoid system, a network of receptors (CB1, CB2) present in the liver, pancreas, fat tissue and brain, which helps regulate appetite and energy metabolism. It is through this system that researchers first suspected a link between cannabinoids and blood sugar.
How does CBD act on glucose metabolism?
Cannabidiol (CBD) acts on metabolism indirectly, and that is what sets it apart from THC. THC directly activates the CB1 receptor, the one that stimulates appetite; CBD, by contrast, binds poorly to this receptor and instead modulates other targets: serotonin receptors (5-HT1A), TRPV1 channels, PPAR-gamma receptors involved in fat storage, and several inflammation pathways. For anyone who wants to understand the difference between CBD and THC, this point explains why the two molecules do not produce the same effects on the body.
On paper, three mechanisms make the hypothesis plausible:
- an anti-inflammatory effect, observed in cells and in animals, which could protect the cells of the pancreas or limit complications;
- an effect on fat tissue, with a possible role in the "browning" of fat cells described in the laboratory;
- an antioxidant effect, studied mainly on blood vessels, the retina and heart muscle.
Almost all of these mechanisms come from in vitro work or studies on rodents. A molecule that acts in a Petri dish does not necessarily reach the right concentration in the human body, at a tolerated dose and taken by mouth. That is the whole gap between a lead and proof, and it is the gap that clinical trials must close.
In this article, we therefore separate three levels of evidence: cells, animals and humans. This avoids confusing an effect measured in rats with a real effect on your blood sugar. Our reading is also based on the original abstracts of the studies, and you will find each source named and dated, so that you can discuss it with a health professional.
What animal studies show
Animal studies are the most extensive body of research on CBD and diabetes, and the most encouraging. In 2006, Lola Weiss's team published an experiment in the journal Autoimmunity on NOD mice, a strain that spontaneously develops autoimmune type 1 diabetes. The incidence of diabetes fell from 86% in untreated mice to 30% in mice receiving CBD, with a decrease in inflammation of the pancreatic islets (insulitis) and in inflammatory cytokines such as TNF-alpha.
Other work on diabetic rats and mice has described a protective effect of CBD on the retina and the heart, two organs affected by the complications of the disease. These results fuel laboratories' interest, but they concern animals treated early, often before the disease appears, at weight-based doses that do not correspond to common human use. In a person who has been diagnosed, a large share of the insulin-producing cells has already been destroyed: preventing is not reversing.
The link between autoimmunity and type 1 diabetes also ties into a broader field, that of autoimmune diseases and chronic inflammation, where CBD is the subject of the same hopes and the same limits: plenty of animal data, very few human trials.
The 2016 trial on type 2 diabetes, the only one testing CBD alone
The trial published in 2016 in Diabetes Care by Khalid Jadoon and his colleagues remains to this day the benchmark for assessing CBD in people with diabetes. It is a randomized, double-blind, placebo-controlled study: neither the patients nor the researchers knew who was receiving what. It included 62 adults with type 2 diabetes not treated with insulin, divided into five groups for 13 weeks.
| Group | Dose | Main result |
|---|---|---|
| CBD alone | 100 mg twice a day | no significant effect on blood sugar compared with placebo; lower resistin and higher GIP compared with baseline |
| THCV alone | 5 mg twice a day | fasting blood sugar lowered by 1.2 mmol/L compared with placebo, better beta cell function |
| CBD + THCV (1:1) | 5 mg / 5 mg twice a day | no significant impact |
| CBD + THCV (20:1) | 100 mg / 5 mg twice a day | no significant impact |
| Placebo | - | comparison group |
The clearest result therefore concerns THCV (tetrahydrocannabivarin), another cannabinoid, and not CBD. Cannabidiol only changed two hormonal markers compared with baseline values: resistin, a fat tissue hormone associated with insulin resistance, decreased, and GIP, a gut hormone that stimulates insulin secretion after a meal, increased. These changes were not found compared with placebo, which prevents any conclusion from being drawn. The authors note that both molecules were well tolerated.
This trial has clear limits: small samples (about a dozen people per group), short duration, and a primary endpoint based on HDL cholesterol rather than blood sugar. It does not prove that CBD is useless; it shows that at 200 mg a day for three months, its effect on blood sugar was not detectable.
Cannabis use and insulin: what observational studies say
Observational studies on cannabis use and diabetes are often wrongly cited as evidence in favor of CBD. The best known, published in 2013 in the American Journal of Medicine by Elizabeth Penner, analyzed data from 4,657 American adults in the NHANES national survey (2005-2010). Among current cannabis users, fasting insulin was 16% lower and the HOMA-IR insulin resistance index 17% lower, with a smaller waist circumference than among people who had never used it.
These figures describe an association, not a cause. Cannabis users differ from others in many respects (age, lifestyle, diet), and the study does not tell us which molecule might be involved: smoked cannabis mainly provides THC, with variable amounts of CBD. The authors also found no dose-response relationship among current users. Applying this result to a CBD oil sold in a store is speculation.
THC, for its part, stimulates appetite, a well-documented effect that complicates control of weight and meals. CBD does not have this effect, and some animal studies even suggest the opposite, a lead explored in research on appetite and excess weight. In humans, no solid study currently shows weight loss due to CBD.
What are the risks of CBD for people with diabetes?
The main risk of CBD for a person with diabetes lies in interactions with medicines, much more than in the molecule itself. Cannabidiol is metabolized by the liver, via cytochrome P450 enzymes. The European package leaflet for Epidyolex, the only purified CBD medicine authorized in the European Union (for certain rare forms of epilepsy), mentions interactions through the CYP3A4 and CYP2C19 enzymes and elevations in liver enzymes (transaminases), especially at high doses and in combination with other medicines.
For a person taking diabetes medication, several points deserve a discussion with their doctor or pharmacist:
- some oral diabetes drugs go through the same liver enzymes, which can change their concentration in the blood;
- many people with diabetes also take anticoagulants, statins or blood pressure medications, which are also affected by these interactions;
- an already weakened liver, common in type 2 diabetes with fatty liver disease, copes less well with an additional load;
- drowsiness, diarrhea and reduced appetite, known side effects of CBD at high doses, can disrupt the balance of meals and therefore of blood sugar.
Cannabis containing THC poses a separate problem. A study published in 2019 in JAMA Internal Medicine, conducted in Colorado among adults living with type 1 diabetes, associates cannabis use with a higher risk of ketoacidosis, a serious complication linked to a lack of insulin. THC can also mask the signs of hypoglycemia or make a person forget an injection. These findings do not directly concern CBD, but they are a reminder that a mislabeled product containing more THC than stated is not harmless.
Type 1 and type 2 diabetes: different expectations
For type 1 diabetes, the interest in CBD concerns preventing or slowing the autoimmune destruction of the pancreas, the lead opened by the experiment on NOD mice. No human trial has yet shown this effect. In a person already diagnosed, insulin remains essential every day, and no plant-based substance can replace it without immediate danger.
For type 2 diabetes, expectations concern insulin sensitivity, weight and low-grade chronic inflammation. The 2016 trial did not confirm any effect of CBD alone on blood sugar; the only clear signal came from THCV. Research is also turning to complications: pain from diabetic neuropathy, retinopathy, heart damage. In these areas, human data remain almost nonexistent, and patients who use CBD to relieve neuropathic pain do so on the basis of testimonials, not trials.
Diabetic neuropathy causes burning, tingling and sometimes intense pain in the feet, symptoms that affect many patients after years of illness. CBD is often presented as a way to help cope with this chronic pain, as with other nerve pain, but no published trial has compared it with a reference medicine in people with diabetes. These symptoms require medical follow-up, because they also signal nerve damage that exposes the person to foot wounds. Retinopathy, another complication, can only be detected by a dilated eye exam, and causes no pain at first.
Several clinical trials are listed on international registries, notably on neuropathy and insulin resistance, but their results have not been published to date. Until they are, only one conclusion holds: CBD has no recognized use in the management of diabetes, and no health authority has approved it for this purpose.
CBD and diabetes: the precautions to know
CBD is not a medicine and has no recognized place in the treatment of diabetes. A person with diabetes who is wondering about a CBD product should first talk to their doctor or pharmacist, with the name of the product and its composition: it is the only way to check for interactions with an ongoing treatment. The following points sum up the known precautions:
- A CBD product sold in France must come from hemp with no more than 0.3% THC; only a batch certificate of analysis makes it possible to check its actual content.
- Any unusual change in blood sugar readings, appetite or alertness should be reported to the doctor without delay.
- CBD gummies, candies and drinks are foodstuffs banned from sale in France, since CBD is not authorized as a food in the European Union; they also add carbohydrates.
- Avoid products containing THC, which stimulate appetite and can mask hypoglycemia.
- Never change your dose of insulin or diabetes medication on your own because you are taking CBD.
CBD sold in France comes from industrial hemp, and only hemp varieties listed in the European catalog may be grown. Yet the THC level varies from one batch of hemp to another, and independent analyses have already found discrepancies between the label and the actual content: an unexpected effect on appetite or alertness may stem from this. Only a recent analysis of the batch provides information on this point, with no absolute guarantee.
CBD oils, flowers and resin do not have the same profile: smoking adds the risks of combustion for the heart and blood vessels, which are already exposed in diabetes. Food supplements and other CBD foodstuffs may not be sold in France, as cannabidiol has no European authorization as a novel food. To place cannabidiol in its overall context, the general information on cannabidiol and its regulation brings together the useful basics about the molecule.
CBD and blood sugar: answers to frequently asked questions
Does CBD lower blood sugar?
CBD did not lower blood sugar in the only randomized trial that tested it on its own in people with type 2 diabetes (Diabetes Care, 2016, 100 mg twice a day for 13 weeks). The decrease measured in this study concerned THCV, another cannabinoid.
Can CBD regulate insulin production?
CBD protected insulin-producing cells in mice predisposed to type 1 diabetes, but no trial has shown this effect in humans. In the 2016 trial, beta cell function improved with THCV, not with CBD.
Is CBD compatible with diabetes treatment?
CBD is not a medicine and can interact with liver enzymes that break down many medicines: only a doctor or pharmacist can judge whether it is compatible with a treatment. CBD never replaces insulin or a prescribed diabetes medication.
Is CBD useful for type 1 diabetes?
CBD has no proven efficacy for type 1 diabetes in humans. The encouraging results come from mice treated before the disease appeared, a situation with no equivalent in a patient who has already been diagnosed.













